Loading...
XSHE
300463
Market cap850mUSD
Oct 09, Last price  
9.58CNY
1D
1.70%
1Q
7.16%
Jan 2017
-60.98%
IPO
-35.11%
Name

Maccura Biotechnology Co Ltd

Chart & performance

D1W1MN
XSHE:300463 chart
P/E
—
P/S
2.69
EPS
—
Div yield, %
1.10%
Shrs. gr., 5y
1.64%
Rev. gr., 5y
-10.27%
Revenues
2.15b
-15.46%
521,308,317606,154,699779,426,580934,846,0791,065,169,0301,488,780,8841,969,983,7282,685,304,9453,222,956,0193,703,877,0053,980,647,1833,608,411,8952,895,769,5112,548,756,6772,154,836,895
Net income
-36m
L
120,415,498158,209,364193,155,929226,210,935251,043,600312,022,762374,132,216444,928,513525,262,646793,917,991956,604,412708,180,365312,618,563126,805,277-35,826,985
CFO
602m
-4.94%
85,546,596110,959,27298,392,339115,090,08433,183,26349,315,14779,033,594193,905,904459,516,3111,094,048,8101,616,683,215843,216,884912,088,535633,798,557602,478,603
Dividend
May 28, 20250.104 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Maccura Biotechnology Co. Ltd. is an enterprise actively involved in the entire process of in vitro diagnostic (IVD) products, from their initial conceptualization and refinement (research and development) to mass production and market delivery. The company also extends related support services, catering to clientele within China and across global territories. Its diverse portfolio features immunoassay solutions, exemplified by chemiluminescence analyzers and their accompanying reagents. In the domain of clinical chemistry, Maccura furnishes reagents vital for evaluating a broad spectrum of physiological indicators, including hepatic and renal function, glucose metabolism, iron levels, specialized proteins, cardiac health, lipid profiles, and coagulation. Moreover, the firm supplies sophisticated clinical laboratory instrumentation, notably automatic hematology systems and both automated and semi-automated coagulation analyzers. The company's offerings further extend to include diagnostic tools for SARS-CoV-2 (COVID-19), such as nucleic acid detection kits and other related items. Additional products consist of glucometers, point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold rapid test kits, molecular diagnostics (e.g., PCR kits), and a variety of pathology supplies. Maccura Biotechnology Co. Ltd. was established in 1994 and maintains its principal operations in Chengdu, China.

Key people

Yong Tang
Chairman of the Board · since 2017
Shan Yin
Finance Director, Director · since 2025
Xin Lin
Chief Human Resource Officer · since 2025
Ping Yu
Chief Administrative Officer · since 2015
Wei Shi
Chief Strategic Investment Officer, Secretary of the Board · since 2016
Hong Deng
Chief Quality Officer, Director · since 2025
Tengxiang Long
Chief Research and Development Officer (Reagents) · since 2020
Weijia Wang
Chief Research and Development Officer (Instruments) · since 2020
Zhen Wang
Chief Production Officer (Instruments) · since 2019
Yueguo Zhou
Chief Production Officer-Reagent · since 2012
Qilin Liu
Director · since 2021
Dengming Wang
Chief Business Officer, Director · since 2023
Mingjian Wu
General Manager, Director · since 2017
Kaicheng Liang
Independent Director · since 2022
Zhenzhong Liao
Independent Director · since 2022
Independent Director · since 2025
IPO date
May 28, 2015
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
成都市高新区百川路16号
成都市, SC 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT